Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 17 of 17

List	Outcome	Time frame	Description
Primary	Change of 24-h average systolic blood pressure measured at baseline and the end of the trial	24 weeks	Difference in the change of 24-h average systolic blood pressure between the intervention and control group is to be analysed.
Secondary	Change of 24-h average systolic blood pressure compared with the baseline	24 weeks	Change of 24-h average systolic blood pressure compared with the baseline at the end of the study (24 weeks) in the intervention group.
Secondary	Change of anti-hypertensive regimen measured at baseline and the end of the trial	24 weeks	Difference in the change of anti-hypertensive regimen between the intervention and control group is to be analysed.
Secondary	Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure measured at baseline and the end of the trial	24 weeks	Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group is to be analysed.
Secondary	Change of home systolic and diastolic pressure measured at baseline and the end of the trial	24 weeks	Difference in the change of home systolic and diastolic pressure between the intervention and control group is to be analysed.
Secondary	Change of office systolic and diastolic pressure measured at baseline and the end of the trial	24 weeks	Difference in the change of office systolic and diastolic pressure between the intervention and control group is to be analysed.
Secondary	Change of blood electrolytes measured at baseline and the end of the trial	24 weeks	Difference in the change of blood electrolytes between the intervention and control group is to be analysed.
Secondary	Change of plasma and urine adrenal hormones measured at baseline and the end of the trial	24 weeks	Difference in the change of plasma and urine adrenal hormones between the intervention and control group is to be analysed.
Secondary	Change of plasma renin measured at baseline and the end of the trial	24 weeks	Difference in the change of plasma renin between the intervention and control group is to be analysed.
Secondary	Change of liver enzymes measured at baseline and the end of the trial	24 weeks	Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group is to be analysed.
Secondary	Change of kidney function measured at baseline and the end of the trial	24 weeks	Difference in the change of serum creatinine in umol/L between the intervention and control group is to be analysed.
Secondary	Change of fasting blood glucose measured at baseline and the end of the trial	24 weeks	Difference in the change of fasting blood glucose in mmol/L between the intervention and control group is to be analysed.
Secondary	Change of lipids profiles measured at baseline and the end of the trial	24 weeks	Difference in the change of lipids profiles (TC, HDL-C, LDL-C, TG) in mmol/L between the intervention and control group is to be analysed.
Other	Change of sex hormones measured at baseline and the end of the trial	24 weeks	Difference in the change of 17-OH, DHEAS, testosterone and estrogen levels between the intervention and control group is to be analysed.
Other	Change of 24-h urine microalbumin measured at baseline and the end of the trial	24 weeks	Difference in the change of 24-h urine microalbumin, microalbumin/creatinine ratio between the intervention and control group is to be analysed.
Other	Change of echocardiography measured at baseline and the end of the trial	24 weeks	Difference in the change of cardiac parameters assessed by echocardiography (IVSd、IVSs、LVPWd, LVPWs, LVEDD, in millimetre(mm), and LVEF(%), LVM in gram) between the intervention and control group is to be analysed.
Other	Change of carotid intima-media thickness assessed by carotid ultrasound at baseline and the end of the trial	24 weeks	Difference in the change of carotid intima-media thickness(CIMT) assessed by carotid ultrasound between the intervention and control group is to be analysed.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03660397/registered

API reference For AI assistants